Everest Medicines Launches Nefecon in China’s Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy

SHANGHAI, April 23, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that Nefecon, the first-in-disease…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.